Author:
Coudert Bruno,Pierga Jean-Yves,Mouret-Reynier Marie-Ange,Kerrou Kaldoun,Ferrero Jean-Marc,Petit Thierry,Du Fanny Le,Dupré Pierre-François,Bachelot Thomas,Gabelle Philippe,Chauvet Marie-Pierre,Coeffic David,Barbe Catherine,Prevost Jean-Briac,Paintaud Gilles,Thibault Gilles,Ferhat Abdennour,Dupin Julien,Berriolo-Riedinger Alina,Arnould Laurent
Reference36 articles.
1. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer;Buzdar;J Clin Oncol,2005
2. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial;Gianni;Lancet Oncol,2016
3. 18F-FDG PET-derived tumor blood flow changes after 1 cycle of neoadjuvant chemotherapy predicts outcome in triple-negative breast cancer;Humbert;J Nucl Med,2016
4. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel;Garcia Garcia-Esquinas;Rev Esp Med Nucl Imagen Mol,2014
5. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO;Gebhart;J Nucl Med,2013
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献